Blinatumomab shows tolerable safety profile and high response rate in paediatric patients with r/r ALL

Tolerable safety profile and high response rate to blinatumomab in paediatric patients with r/r ALL
Tolerable safety profile and high response rate to blinatumomab in paediatric patients with r/r ALL